Merck to Acquire Tilos Therapeutics
Dateline City:
KENILWORTH, N.J.
Merck Gains Portfolio of Investigational Antibodies Modulating TGFβ
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that it has entered into a definitive agreement to
acquire Tilos Therapeutics, a privately held biopharmaceutical company
developing therapeutics targeting the latent TGFβ complex for the
treatment of cancer, fibrosis and autoimmune diseases.
Language:
English
Contact:
Media:
Pamela Eisele
(267) 305-3558
Ian McConnell
(908) 740-1921
Investors:
Teri Loxam
(908) 740-1986
Michael DeCarbo
(908) 740-1807
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck
Read Original Article: Merck to Acquire Tilos Therapeutics »
